Insiders Abliva AB

Equities

ABLI

SE0002575340

Delayed Nasdaq Stockholm Other stock markets 04:53:43 2024-05-15 EDT			5-day change	1st Jan Change
0.2 ^SEK	+1.63%		+4.28%	-18.53%

02-23	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023	23-05-04	AQ
Abliva AB Announces Resignation of Edwin Moses as Director	23-05-04	CI
Abliva AB Elects Edwin Moses as New Board Member	23-03-08	CI
Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings	23-02-13	AQ
Abliva Announces CEO Changes, with Effect from February 3rd	21-01-20	CI
Abliva AB Announces Resignation of Magnus Persson From Board of Directors	20-10-08	CI
NeuroVive Pharmaceutical AB will Change its Name to Abliva AB	20-05-27	CI
NeuroVive Pharmaceutical AB Elects Roger Franklin as New Board Member; Approves Amendment to the Articles of Association	20-05-20	CI
NeuroVive Pharmaceutical : Nomination Committee amends its proposal to the 2020 Annual General Meeting	20-04-29	AQ
NeuroVive Pharmaceutical : Nomination Committee amends its proposal to the 2020 Annual General Meeting	20-04-28	AQ
NeuroVive Pharmaceutical AB Elects Magnus Persson as New Board Member	19-04-25	CI
NeuroVive Pharmaceutical AB Appoints Denise Goode as New Board Member	18-04-27	CI
NeuroVive Pharmaceutical AB Announces Board Changes	17-11-07	CI
NeuroVive Pharmaceutical AB Appoints Daniel Schale as Director of Communications	17-10-04	CI
NeuroVive Pharmaceutical AB Appoints Mark Farmery as Vice President Business Development	17-09-01	CI
Neurovive Pharmaceutical AB Appoints Philippe Gallay and Massimo Pinzani as Scientific Advisors	17-02-22	CI
NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee	16-10-26	PU
NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee	16-10-26	BU
NeuroVive Pharmaceutical AB's Chief Operating Officer Jan Nilsson Leaves the Company	16-08-24	CI
NeuroVive Pharmaceutical AB Appoints Cecilia Hofvander as Investor Relations and Communications Director, Effective June 1, 2016	16-04-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Abliva AB

Equities

ABLI

SE0002575340

Insiders

Filters